Dermata Therapeutics Warrant
DRMAW
DRMAW was delisted on the 17th of August, 2026.
2 hedge funds and large institutions have $14.5K invested in Dermata Therapeutics Warrant in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.61% less ownership
Funds ownership: 1.32% → 0.71% (-0.61%)
90% less capital inflows, than outflows
Capital inflows: $25 | Capital outflows: $253
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$25 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$253 |
DRMAW Hedge Fund Activity: Q1 2026 in Review
2 of the 8,211 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics Warrant (DRMAW) for Q1 2026, worth a combined $14.5K — down 48% from $28.1K a quarter earlier.
Fund positioning in DRMAW was balanced in Q1 2026: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $25. The largest seller was Susquehanna International Group, exiting entirely with an estimated $253 sold.
- 2 institutional investors held Dermata Therapeutics Warrant (DRMAW) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $14.5K of Dermata Therapeutics Warrant stock for Q1 2026, down 48% quarter-over-quarter.
- 1 fund opened new Dermata Therapeutics Warrant positions in Q1 2026 and 1 closed out, a net change of 0 holders.
- The largest Dermata Therapeutics Warrant buyer in Q1 2026 was UBS Group, an estimated $25 added.
- The largest Dermata Therapeutics Warrant seller in Q1 2026 was Susquehanna International Group, an estimated $253 sold.
Based on aggregated 13F filings for Q1 2026.